Skip to content
Trial Eligibility
Menu

Reducing Barriers to Lifestyle Modification for Newly Diagnosed MASLD

NCT06483711

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of liver disease in the world. It is estimated that 38% of American children with obesity have steatotic liver disease. Patients of Hispanic ethnicity are disproportionately at risk of developing MASLD. This study intends to provide insight to barriers of recommended care for pediatric patients with Hispanic ethnicity and a new diagnosis of MASLD.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Metabolic Dysfunction-associated Steatotic Liver Disease

Eligibility basics and study details

Study type
Interventional
Phase
Not applicable
Ages
10 to 17 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
Stanford University
Last updated on ClinicalTrials.gov
November 19, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

California · 1

  • LPCH Stanford Weight Clinic · Palo Alto, CA

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.